Rétine
Open Access
Issue
Med Sci (Paris)
Volume 36, Number 10, Octobre 2020
Rétine
Page(s) 893 - 899
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020160
Published online 07 October 2020
  1. Thorne JE, Suhler E, Skup M, et al. Prevalence of noninfectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmol 2016 ; 134 : 1237–1245. [CrossRef] [PubMed] [Google Scholar]
  2. Daudin JB Épidémiologie. Uvéites. Paris : Masson 2010 : 111. [Google Scholar]
  3. Brézin AP. Sémiologie et classification des uvéites. Uvéites. Paris: Masson, 2010. [Google Scholar]
  4. Massa H, Georgoudis P, Panos GD. Dexamethasone intravitreal implant (Ozurdex®) for macular edema secondary to noninfectious uveitis: a review of the literature. Ther Deliv 2019 ; 10 : 343–351. [CrossRef] [PubMed] [Google Scholar]
  5. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-αlpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004 ; 23 : 617–637. [CrossRef] [PubMed] [Google Scholar]
  6. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987 ; 262 : 6951–6954. [PubMed] [Google Scholar]
  7. van Schie KA, Ooijevaar-de Heer P, Dijk L, et al. Therapeutic TNF inhibitors can differentially stabilize trimeric TNF by inhibiting monomer exchange. Sci Rep 2016 ; 6 : 32747. [CrossRef] [PubMed] [Google Scholar]
  8. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994 ; 76 : 959–962. [CrossRef] [PubMed] [Google Scholar]
  9. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995 ; 83 : 793–802. [CrossRef] [PubMed] [Google Scholar]
  10. Yang S, Wang J, Brand DD, Zheng SG. Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications. Front Immunol 2018 ; 9 : 784. [CrossRef] [PubMed] [Google Scholar]
  11. Kowalczuk L, Touchard E, Camelo S, et al. Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle. Invest Ophthalmol Vis Sci 2009 ; 50 : 1761–1768. [CrossRef] [PubMed] [Google Scholar]
  12. Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res 2011 ; 31 : 733–744. [CrossRef] [PubMed] [Google Scholar]
  13. Bauer D, Kasper M, Walscheid K, et al. Multiplex cytokine analysis of aqueous humor in juvenile idiopathic arthritis-associated anterior uveitis with or without secondary glaucoma. Front Immunol 2018 ; 9 : 708. [CrossRef] [PubMed] [Google Scholar]
  14. Bonacini M, Soriano A, Cimino L, et al. Cytokine profiling in aqueous humor samples from patients with non-infectious uveitis associated with systemic inflammatory diseases. Front Immunol 2020; 11 : 358. [CrossRef] [PubMed] [Google Scholar]
  15. Lim H, Lee SH, Lee HT, et al. Structural biology of the TNFα antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci 2018 ; 19 : [Google Scholar]
  16. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002 ; 301 : 418–426. [Google Scholar]
  17. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action : a comprehensive review. Pharmacol Ther 2008 ; 117 : 244–279. [Google Scholar]
  18. Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 2016 ; 22 : 9300–9313. [CrossRef] [PubMed] [Google Scholar]
  19. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009 ; 131 : 308–316. [CrossRef] [PubMed] [Google Scholar]
  20. Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 2011 ; 53 : 207–214. [Google Scholar]
  21. Adler BL, Wang CJ, Bui T-L, et al. Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum 2019 ; 48 : 1093–1104. [CrossRef] [PubMed] [Google Scholar]
  22. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ. Biogeas study group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008 ; 87 : 345–364. [Google Scholar]
  23. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med 2016 ; 375 : 932–943. [Google Scholar]
  24. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (Visual II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016 ; 388 : 1183–1192. [CrossRef] [PubMed] [Google Scholar]
  25. Celiker H, Kazokoglu H, Direskeneli H. Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents. BMC Ophthalmol 2018 ; 18 : 261. [CrossRef] [PubMed] [Google Scholar]
  26. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (Focus) initiative. Ophthalmology 2018 ; 125 : 757–773. [Google Scholar]
  27. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006 ; 113 : 860–864.e2. [Google Scholar]
  28. Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum 2015 ; 45 : 361–368. [CrossRef] [PubMed] [Google Scholar]
  29. Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology 2014 ; 121 : 1877–1884. [Google Scholar]
  30. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017 ; 376 : 1637–1646. [Google Scholar]
  31. Frantz C, Portier A, Etcheto A, et al. Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients. Clin Exp Rheumatol 2019 ; 37 : 26–31. [Google Scholar]
  32. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006 ; 65 : 1631–1634. [Google Scholar]
  33. Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009 ; 68 : 696–701. [Google Scholar]
  34. Lie E, Lindström U, Zverkova-Sandström T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 2017 ; 76 : 1515–1521. [Google Scholar]
  35. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005 ; 52 : 2447–2451. [CrossRef] [PubMed] [Google Scholar]
  36. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis?. A registry-based study. Arthritis Rheum 2007 ; 56 : 3248–3252. [Google Scholar]
  37. El Sanharawi M, Kowalczuk L, Touchard E, et al. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res 2010 ; 29 : 443–465. [CrossRef] [PubMed] [Google Scholar]
  38. Bouquet C, Vignal Clermont C, Galy A, et al. Immune response and intraocular inflammation in patients with leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 Carrying the ND4 gene: a secondary analysis of a phase 1/2 clinical trial. JAMA Ophthalmol 2019 ; 137 : 399–406. [CrossRef] [PubMed] [Google Scholar]
  39. Davis JL. The blunt end: surgical challenges of gene therapy for inherited retinal diseases. Am J Ophthalmol 2018; 196 : xxv–xxix. [CrossRef] [PubMed] [Google Scholar]
  40. André F, Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 2004 ; 11(suppl 1): S33–S42. [CrossRef] [PubMed] [Google Scholar]
  41. Garcia-Frigola C, Carreres MI, Vegar C, Herrera E. Gene delivery into mouse retinal ganglion cells by in utero electroporation. BMC Dev Biol 2007 ; 7 : 103. [CrossRef] [PubMed] [Google Scholar]
  42. De Melo J, Blackshaw S. In vivo electroporation of developing mouse retina. Methods Mol Biol Clifton NJ 2018 ; 1715 : 101–111. [CrossRef] [Google Scholar]
  43. Latella MC, Di Salvo MT, Cocchiarella F, et al. In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR/Cas9 in the mouse retina. Mol Ther Nucleic Acids 2016 ; 5 : e389. [CrossRef] [PubMed] [Google Scholar]
  44. Touchard E, Berdugo M, Bigey P, et al. Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina. Mol Ther J Am Soc Gene Ther 2012 ; 20 : 1559–1570. [CrossRef] [Google Scholar]
  45. El Sanharawi M, Touchard E, Benard R, et al. Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization. Gene Ther 2013 ; 20 : 1093–1103. [CrossRef] [PubMed] [Google Scholar]
  46. Bloquel C, Bourges JL, Touchard E, et al. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev 2006 ; 58 : 1224–1242. [CrossRef] [PubMed] [Google Scholar]
  47. Touchard E, Kowalczuk L, Bloquel C, et al. The ciliary smooth muscle electrotransfer : basic principles and potential for sustained intraocular production of therapeutic proteins. J Gene Med 2010 ; 12 : 904–919. [CrossRef] [PubMed] [Google Scholar]
  48. Touchard E, Benard R, Bigot K, et al. Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: preclinical evaluation of the medicinal product. J Control Release 2018 ; 285 : 244–251. [CrossRef] [PubMed] [Google Scholar]
  49. Touchard E, Bloquel C, Bigey P, et al. Effects of ciliary muscle plasmid electrotransfer of TNF-αlpha soluble receptor variants in experimental uveitis. Gene Ther 2009 ; 16 : 862–873. [CrossRef] [PubMed] [Google Scholar]
  50. Touchard E, Heiduschka P, Berdugo M, et al. Non-viral gene therapy for GDNF production in RCS rat: the crucial role of the plasmid dose. Gene Ther 2012 ; 19 : 886–898. [CrossRef] [PubMed] [Google Scholar]
  51. Picard E, Le Rouzic Q, Oudar A, et al. Targeting iron-mediated retinal degeneration by local delivery of transferrin. Free Radic Biol Med 2015 ; 89 : 1105–1121. [CrossRef] [PubMed] [Google Scholar]
  52. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010 ; 6 : 94–101. [CrossRef] [PubMed] [Google Scholar]
  53. Tezel G. TNF-αlpha signaling in glaucomatous neurodegeneration. Prog Brain Res 2008 ; 173 : 409–421. [CrossRef] [PubMed] [Google Scholar]
  54. Wei X, Cho K-S, Thee EF, et al. Neuroinflammation and microglia in glaucoma: time for a paradigm shift. J Neurosci Res 2019 ; 97 : 70–76. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.